Kistler-tiffany Companies Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Kistler-tiffany Companies reduced its stake in Amgen by 0.41% during the most recent quarter end. The investment management company now holds a total of 12,379 shares of Amgen which is valued at $1,994,257 after selling 51 shares in Amgen , the firm said in a disclosure report filed with the SEC on Jul 6, 2016.Amgen makes up approximately 1.01% of Kistler-tiffany Companies’s portfolio.

Other Hedge Funds, Including , Summit Financial Wealth Advisors boosted its stake in AMGN in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 2,334 shares of Amgen which is valued at $376,007. Amgen makes up approx 0.16% of Summit Financial Wealth Advisors’s portfolio.Indiana Trust Investment Management Co boosted its stake in AMGN in the latest quarter, The investment management firm added 75 additional shares and now holds a total of 2,234 shares of Amgen which is valued at $344,639. Amgen makes up approx 0.18% of Indiana Trust Investment Management Co’s portfolio.Integrated Investment Consultants boosted its stake in AMGN in the latest quarter, The investment management firm added 2,200 additional shares and now holds a total of 4,841 shares of Amgen which is valued at $746,821. Amgen makes up approx 0.39% of Integrated Investment Consultants’s portfolio.New England Research Management reduced its stake in AMGN by selling 275 shares or 2.86% in the most recent quarter. The Hedge Fund company now holds 9,340 shares of AMGN which is valued at $1,440,882. Amgen makes up approx 1.26% of New England Research Management’s portfolio.First Financial Bank N.a. – Trust Division boosted its stake in AMGN in the latest quarter, The investment management firm added 18 additional shares and now holds a total of 1,884 shares of Amgen which is valued at $290,645. Amgen makes up approx 0.06% of First Financial Bank N.a. – Trust Division’s portfolio.

Amgen closed down -0.92 points or -0.57% at $160.18 with 24,64,686 shares getting traded on Monday. Post opening the session at $161.36, the shares hit an intraday low of $160 and an intraday high of $162.32 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.